Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Inside Epstein’s infamous ‘birthday book’: Clinton’s note, poolside...
Whole milk makes a comeback in new MAHA...
Hawley pushes legal action against Meta after whistleblowers...
As Trump’s bawdy birthday message to Jeffrey Epstein...
Elon Musk agrees with JD Vance on the...
Scalise hints GOP may push nationwide crime crackdown...
Harris admits Biden ‘got tired,’ denies ‘conspiracy’ to...
GOP senator compares Israel’s Hamas fight to US...
Trump calls for death penalty for suspect in...
Jury selection still underway in Ryan Routh trial,...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by admin November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS

previous post
HyProMag USA Feasibility Study Demonstrates Robust Economics and the Opportunity to Develop a Major New, Domestic Source of Recycled Rare Earths Magnets for the United States
next post
Stop funding the woke and the stupid

You may also like

Steve Bannon warns of world conflict that could...

January 20, 2025

Trump shooting task force says DHS, Secret Service...

December 11, 2024

House Republicans lament Trump’s ‘terrible’ debate performance: ‘Let...

September 12, 2024

Trump tax cut plan heads for House-wide vote...

February 25, 2025

Informant accused of feeding FBI bogus Biden information...

December 13, 2024

Canadian leader meets with Trump at Mar-a-Lago to...

January 13, 2025

Top Senate Republican ready to ‘roll over’ Democrats...

August 30, 2025

Federal judge denies Trump admin’s effort to ban...

March 27, 2025

Durbin obstruction threat chills Senate as Trump nominees...

June 5, 2025

Senate unanimously passes bill bolstering presidential candidates’ Secret...

September 25, 2024

Recent Posts

  • Inside Epstein’s infamous ‘birthday book’: Clinton’s note, poolside candids and bizarre animal pics
  • Whole milk makes a comeback in new MAHA children’s health strategy
  • Hawley pushes legal action against Meta after whistleblowers detail child abuse in VR
  • As Trump’s bawdy birthday message to Jeffrey Epstein appears, he still insists he never sent it
  • Elon Musk agrees with JD Vance on the ‘big lie the Democrats told about violent crime’

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (913)
    • Investing (2,932)
    • Politics (3,601)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.